COMMON INITIAL DOSING REGIMENS

• A common regimen is 100 mcg to 300 mcg subcutaneously once daily for 10–20 days, with cycles repeated every few months as needed. Some protocols recommend combination therapy with other neuropeptides for synergistic effects.

MECHANISM OF ACTION

• Pinealon is a synthetic tripeptide (Glu-Asp-Arg) that acts as a bioregulator in the central nervous system. It is believed to modulate gene expression involved in neuronal metabolism, oxidative stress resistance, and brain plasticity. Animal studies suggest Pinealon may enhance mitochondrial function, reduce apoptosis in neurons, and improve cerebral blood flow.

• Its neuroprotective effects may stem from improved cellular energy balance and reduced excitotoxic or oxidative injury, which are key contributors to age-related cognitive decline.

COMMON SIDE EFFECTS

• Neurologic: Headache, vivid dreams, or mild insomnia if taken too late in the day.

• General: Mild anxiety, dizziness, or transient fatigue.

• Injection Site: Redness, itching, or minor swelling.

• Rare: Gastrointestinal discomfort or allergic skin reactions

CONTRAINDICATIONS

• Absolute: Known hypersensitivity to Pinealon or its excipients.

• Relative: Use with caution in individuals with epilepsy or seizure disorders, as central nervous system–active agents may lower seizure threshold in rare cases. Safety in pregnancy and breastfeeding has not been established.

COMPARISON WITH OTHER AGENTS

• Semax/Selank: Like Pinealon, these peptides are used for cognitive support. Semax and Selank act primarily via modulation of neurotransmitters and neurotrophic factors, whereas Pinealon may act more on cellular repair, metabolism, and anti-apoptotic pathways.

• NAD+ Precursors (NMN, NR): These support energy metabolism and mitochondrial function systemically. Pinealon appears to have a more CNS-specific protective role.

• Racetams or Stimulants: These may enhance short-term cognition through neurotransmitter stimulation, while Pinealon is intended for longer-term neuroprotection and repair.

EXPERIMENTAL TREATMENT DISCLAIMER:

• Pinealon is not approved by the FDA for any medical indication. Its use in humans is considered experimental. While preclinical and limited human data suggest potential neuroprotective and cognitive benefits, robust clinical studies are lacking. The long-term safety, optimal dosing, and efficacy of Pinealon have not been established. The patient acknowledges the investigational nature of this therapy and assumes full responsibility for its use.

MORE INFORMATION

• FDA Safety Data Sheet not available (experimental peptide).